Perspectives on Life Sciences
209 total results. Page 1 of 9.
Arent Fox continues to monitor the FDA activities and scientific reports on COVID-19 and the novel coronavirus.
The coronavirus (COVID-19) outbreak has led to a dramatic increase in the demand for, and a shortage of, hand sanitizer in the US.
FDA has just published a new Guidance that will allow for the suspension of reporting of certain adverse event reports while the COVID-19 pandemic continues.
FDA has just issued what it calls “FAQs on Diagnostic Testing for SARS-CoV-2” that provides information on which tests and which testing laboratories have received Emergency Use Authorization for the testing for the COVID-19 virus.
Arent Fox has been monitoring daily updates from the top scientific journals and similar sources to get the most accurate information as soon as it is first made available. Here is a brief summary of the key issues that are of concern.
Arent Fox LLP is pleased to announce the expansion of its Patent practice and Life Sciences group with the addition of Counsels Daniel C. Stelter and Laurence H. Posorske, Ph.D. Mr. Stelter joins the firm’s San Francisco office, while Mr. Posorske joins Arent Fox in Washington, DC.
Last month, Representatives Sean Patrick Maloney (NY-18) and Grace Meng (NY-6) introduced the Natural Cosmetics Act that would define the term “natural” as it relates to personal care products and give the US Food and Drug Administration (FDA) authority to enforce the new requirements.
IP Partner Pamela M. Deese is a featured speaker at the Brand Protection Summit, co-hosted by CounterFind and Warner Music Group on November 7th, 2019 in New York.
Twenty-five Arent Fox LLP practices have been recognized in the 2020 “Best Law Firms” rankings that are published annually by US News & World Report and Best Lawyers.
Partner Alexander H. Spiegler will present “US Case Law Update” at the CIPA Annual Life Sciences Conference 2019 on November 11, 2019.
On October 18, Arent Fox’s New York office will host a one-of-a-kind event on behalf of the New York State Bar Association that focuses on the intersection of FDA and sports law.
Please join us on October 10 for an engaging lunch program that will address the convergence of medicine and the Internet of Things.
The protection of intellectual property in the biotech industry is critical. Patents are the most common form of IP protection for biotech inventions.
Life Sciences Counsel Brian Malkin is the keynote speaker of the Michigan Institute for Clinical & Health Research’s Medical Devices in Academic Research Symposium on October 16, 2019. Brian will also moderate a panel discussion during the event.
Counsel Brian Malkin will speak on a panel about FDA’s role in the regulation of cannabis at the Food and Drug Law Institute Legal and Practical Issues in the Evolving World of Cannabis Regulation conference on November 18-19, 2019.
Life Sciences Counsel Brian Malkin will speak at AdvaMed’s Investigational Device Exemption (IDE) Submissions Workshop in Washington, DC on October 9.
WASHINGTON — Fifty Arent Fox LLP attorneys have been rated as leaders in their profession by The Best Lawyers in America 2020.
Life Sciences Counsel Stan Abramson will speak on a panel at a Farm Foundation Forum about the challenges and opportunities of implementing a new biotechnology regulation review process on July 23, 2019, at the National Press Club.
Life Sciences Partner Karen Ellis Carr will speak at the Farm Foundation® Forum, “Gene Editing: Opportunities and Challenges,” at the National Press Club on July 17, 2018.
Arent Fox LLP is pleased to announce the expansion of its nationally recognized Food, Drug, Medical Device & Cosmetic practice with the addition of Partner Deborah M. Shelton.
On June 6, the US Department of Agriculture (USDA or Agency) released its proposed revision to Part 340, the regulations implementing USDA’s authority over genetically engineered (GE) organisms, including GE plants.
Arent Fox Counsel Brian Malkin was quoted in a recent Pink Sheet analysis about the Food and Drug Administration (FDA)’s new efforts at transparency in the generic drug space.
The Action Plan is intended to clarify the agency’s science- and-risk-based approach to regulating such products with the stated goals of fostering innovation, enhancing public communication and outreach, and increasing coordination between FDA and its federal and international counterparts.
Last week, USDA’s Agricultural Marketing Service convened a webinar to accept public comments on implementing the hemp provisions included in the 2018 farm bill.
Arent Fox hosted the Institute of Food Technologies and American Society for Nutrition’s 8th Annual Food Policy Impact meeting at the DC office on February 11-12th.